Advanced search
Publication Cover
Journal of Medical Economics Volume 25, 2022 - Issue 1
Submit an article Journal homepage
1,827
Views
3
CrossRef citations to date
0
Altmetric
Neurology

Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK

S. Montgomerya Costello Medical Consulting Ltd, Cambridge, UKORCID Iconhttps://orcid.org/0000-0002-8481-5850
ORCID Icon,
F. Woodhousea Costello Medical Consulting Ltd, Cambridge, UKORCID Iconhttps://orcid.org/0000-0002-6958-840X
ORCID Icon,
U. Vudumulab Novartis Ireland Limited, Dublin, IrelandORCID Iconhttps://orcid.org/0000-0002-7407-4059
ORCID Icon,
K. Gudalac Novartis Healthcare Private Limited, Hyderabad, India
,
M. Duddyd Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UKORCID Iconhttps://orcid.org/0000-0003-2393-8977
ORCID Icon &
M. Kroese Novartis Pharmaceuticals UK Ltd, London, UKCorrespondence[email protected]
Pages 669-678 | Received 04 Apr 2022, Accepted 12 May 2022, Published online: 27 May 2022

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Ralph HB Benedict, Pamela Vo, Nicholas Adlard, Olwyn Grennan, Ashley Enstone, Daisy Bridge, Robin Wyn & Stanley L Cohan. (2024) Disutility of Cognitive Processing Speed (CPS) Impairment in the Context of Multiple Sclerosis: A Time Trade-Off (TTO) Elicitation Study. ClinicoEconomics and Outcomes Research 16, pages 55-67.
Read now

Articles from other publishers (2)

Nasrin Abulhasanbeigi Gallehzan, Majid Khosravi, Khosro Jamebozorgi, Nazanin Mir, Habib Jalilian, Samira Soleimanpour, Saeed Hoseini, Aziz Rezapour & Abbas Eshraghi. (2024) Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing–remitting multiple sclerosis: a systematic review. Health Economics Review 14:1.
Crossref
Martin Vališ, Anat Achiron, Hans Peter Hartung, Jan Mareš, Veronika Tichá, Pavel Štourač, Simona Halusková, Francesco Angelucci & Zbyšek Pavelek. (2023) The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis. Drugs in R&D 23:4, pages 331-338.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.